By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market Tuesday that its fourth quarter sales grew 17 percent or 11 percent organically.

For the quarter ended Dec. 31, 2011, the molecular diagnostics firm generated sales of $334.4 million, up from $286 million a year ago, surpassing analyst estimates of $323.3 million.

The acquisitions of Cellestis and Ipsogen provided 6 percentage points to growth, the company said, adding that currency had no effect on sales growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.